S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69

BioCryst Pharmaceuticals Stock Forecast, Price & News

-0.20 (-1.43%)
(As of 01/21/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
4.47 million shs
Average Volume
6.32 million shs
Market Capitalization
$2.46 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive BCRX News and Ratings via Email

Sign-up to receive the latest news and ratings for BioCryst Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

BioCryst Pharmaceuticals logo

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc. is a commercial-stage biotechnology company that discovers novel, oral, and small-molecule medicines. The firm focuses on the treatment of rare diseases in which unmet medical needs exist and an enzyme in the biological pathway of the disease. Its programs include BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for marburg virus disease and yellow fever. The company was founded in 1986 and is headquartered in Durham, NC.


See More Headlines

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$17.81 million
Book Value
($0.11) per share


Net Income
$-182.81 million
Net Margins
Pretax Margin




Free Float
Market Cap
$2.46 billion

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Social Links


Overall MarketRank

2.20 out of 5 stars

Medical Sector

391st out of 1,418 stocks

Biological Products, Except Diagnostic Industry

58th out of 206 stocks

Analyst Opinion: 3.4Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -

BioCryst Pharmaceuticals (NASDAQ:BCRX) Frequently Asked Questions

Is BioCryst Pharmaceuticals a buy right now?

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioCryst Pharmaceuticals in the last twelve months. There are currently 3 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BioCryst Pharmaceuticals stock.
View analyst ratings for BioCryst Pharmaceuticals
or view top-rated stocks.

How has BioCryst Pharmaceuticals' stock been impacted by Coronavirus (COVID-19)?

BioCryst Pharmaceuticals' stock was trading at $2.59 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, BCRX stock has increased by 432.0% and is now trading at $13.78.
View which stocks have been most impacted by COVID-19

When is BioCryst Pharmaceuticals' next earnings date?

BioCryst Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for BioCryst Pharmaceuticals

How were BioCryst Pharmaceuticals' earnings last quarter?

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) issued its earnings results on Tuesday, November, 2nd. The biotechnology company reported ($0.33) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.29) by $0.04. The biotechnology company had revenue of $40.99 million for the quarter, compared to analysts' expectations of $37.75 million. During the same quarter in the prior year, the business posted ($0.26) EPS.
View BioCryst Pharmaceuticals' earnings history

What price target have analysts set for BCRX?

11 brokers have issued 1 year target prices for BioCryst Pharmaceuticals' shares. Their forecasts range from $14.00 to $30.00. On average, they anticipate BioCryst Pharmaceuticals' stock price to reach $19.82 in the next twelve months. This suggests a possible upside of 43.8% from the stock's current price.
View analysts' price targets for BioCryst Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are BioCryst Pharmaceuticals' key executives?

BioCryst Pharmaceuticals' management team includes the following people:
  • Jon P. Stonehouse, President, Chief Executive Officer & Director
  • Michael L. Jones, Executive Director-Finance
  • Anthony Doyle, Chief Financial Officer, Treasurer & Senior VP
  • William P. Sheridan, Chief Medical Officer & Senior Vice President
  • Helen M. Thackray, Chief Research & Development Officer

What is Jon P. Stonehouse's approval rating as BioCryst Pharmaceuticals' CEO?

2 employees have rated BioCryst Pharmaceuticals CEO Jon P. Stonehouse on Glassdoor.com. Jon P. Stonehouse has an approval rating of 40% among BioCryst Pharmaceuticals' employees. This puts Jon P. Stonehouse in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of BioCryst Pharmaceuticals own?

What is BioCryst Pharmaceuticals' stock symbol?

BioCryst Pharmaceuticals trades on the NASDAQ under the ticker symbol "BCRX."

Who are BioCryst Pharmaceuticals' major shareholders?

BioCryst Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Edge Wealth Management LLC (0.02%), Diversified Trust Co (0.01%) and Cutler Group LP (0.00%). Company insiders that own BioCryst Pharmaceuticals stock include Alane P Barnes, Anthony Doyle, George B Abercrombie, George B Abercrombie, Jon P Stonehouse, Nancy J Hutson, Vincent Milano, William P Sheridan and Yarlagadda S Babu.
View institutional ownership trends for BioCryst Pharmaceuticals

Which institutional investors are selling BioCryst Pharmaceuticals stock?

BCRX stock was sold by a variety of institutional investors in the last quarter, including Cutler Group LP. Company insiders that have sold BioCryst Pharmaceuticals company stock in the last year include Alane P Barnes, George B Abercrombie, Jon P Stonehouse, Nancy J Hutson, William P Sheridan, and Yarlagadda S Babu.
View insider buying and selling activity for BioCryst Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying BioCryst Pharmaceuticals stock?

BCRX stock was purchased by a variety of institutional investors in the last quarter, including Diversified Trust Co, and Edge Wealth Management LLC. Company insiders that have bought BioCryst Pharmaceuticals stock in the last two years include Anthony Doyle, and Vincent Milano.
View insider buying and selling activity for BioCryst Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of BioCryst Pharmaceuticals?

Shares of BCRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BioCryst Pharmaceuticals' stock price today?

One share of BCRX stock can currently be purchased for approximately $13.78.

How much money does BioCryst Pharmaceuticals make?

BioCryst Pharmaceuticals has a market capitalization of $2.46 billion and generates $17.81 million in revenue each year. The biotechnology company earns $-182.81 million in net income (profit) each year or ($1.27) on an earnings per share basis.

How many employees does BioCryst Pharmaceuticals have?

BioCryst Pharmaceuticals employs 246 workers across the globe.

When was BioCryst Pharmaceuticals founded?

BioCryst Pharmaceuticals was founded in 1986.

What is BioCryst Pharmaceuticals' official website?

The official website for BioCryst Pharmaceuticals is www.biocryst.com.

Where are BioCryst Pharmaceuticals' headquarters?

BioCryst Pharmaceuticals is headquartered at 4505 EMPEROR BOULEVARD SUITE 200, DURHAM NC, 27703.

How can I contact BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals' mailing address is 4505 EMPEROR BOULEVARD SUITE 200, DURHAM NC, 27703. The biotechnology company can be reached via phone at (919) 859-1302, via email at [email protected], or via fax at 919-859-1314.

This page was last updated on 1/23/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.